CRISPR Therapeutics (BRSE:1CG) - Stock Price, News & Analysis

1CG Stock Overview

1CG fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	2/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Trading at 30.4% below our estimate of its fair value

Revenue is forecast to grow 37.62% per year

Risk Analysis

Highly volatile share price over the past 3 months

Currently unprofitable and not forecast to become profitable over the next 3 years

Shareholders have been diluted in the past year

CRISPR Therapeutics AG Competitors

Basilea Pharmaceutica

SWX:BSLN

CHF503.5m

Idorsia

SWX:IDIA

CHF348.7m

Kuros Biosciences

SWX:KURN

CHF277.8m

Molecular Partners

SWX:MOLN

CHF110.1m

Price History & Performance

Summary of all time highs, changes and price drops for CRISPR Therapeutics
Historical stock prices
Current Share Price	US$52.28
52 Week High	US$0
52 Week Low	US$0
Beta	1.74
1 Month Change	-18.40%
3 Month Change	1.94%
1 Year Change	11.63%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-20.25%

Recent updates

Shareholder Returns

	1CG	CH Biotechs	CH Market
7D	-8.5%	-5.2%	-1.8%
1Y	11.6%	13.2%	-3.8%

Return vs Industry: 1CG underperformed the Swiss Biotechs industry which returned 15.8% over the past year.

Return vs Market: 1CG exceeded the Swiss Market which returned -3.6% over the past year.

Price Volatility

Is 1CG's price volatile compared to industry and market?
1CG volatility
1CG Average Weekly Movement	10.5%
Biotechs Industry Average Movement	7.6%
Market Average Movement	3.5%
10% most volatile stocks in CH Market	7.4%
10% least volatile stocks in CH Market	1.9%

Stable Share Price: 1CG's share price has been volatile over the past 3 months.

Volatility Over Time: 1CG's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of Swiss stocks.

About the Company

Founded	Employees	CEO	Website
2013	407	Sam Kulkarni	www.crisprtx.com

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, immune-oncology and autoimmune, in vivo, and type 1 diabetes.

CRISPR Therapeutics AG Fundamentals Summary

How do CRISPR Therapeutics's earnings and revenue compare to its market cap?
1CG fundamental statistics
Market cap	CHF4.29b
Earnings (TTM)	-CHF139.62m
Revenue (TTM)	CHF337.40m

12.7x

P/S Ratio

-30.7x

P/E Ratio

Is 1CG overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
1CG income statement (TTM)
Revenue	US$371.21m
Cost of Revenue	US$517.58m
Gross Profit	-US$146.38m
Other Expenses	US$7.23m
Earnings	-US$153.61m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-1.81
Gross Margin	-39.43%
Net Profit Margin	-41.38%
Debt/Equity Ratio	0%

How did 1CG perform over the long term?

See historical performance and comparison

1CG Stock Overview

Rewards

Risk Analysis

CRISPR Therapeutics AG Competitors

SWX:BSLN

CHF503.5m

SWX:IDIA

CHF348.7m

SWX:KURN

CHF277.8m

SWX:MOLN

CHF110.1m

Price History & Performance

Recent News & Updates

Now 23% undervalued

CRISPR Therapeutics AG, Annual General Meeting, May 30, 2024

Full year 2023 earnings released: US$1.94 loss per share (vs US$8.36 loss in FY 2022)

New minor risk - Shareholder dilution

CRISPR Therapeutics AG has filed a Follow-on Equity Offering in the amount of $279.999863 million.

CRISPR Therapeutics Announces U.S. Food and Drug Administration (FDA) Approval of CASGEVY™ for the Treatment of Transfusion-Dependent Beta Thalassemia

Recent updates

Now 23% undervalued

CRISPR Therapeutics AG, Annual General Meeting, May 30, 2024

Full year 2023 earnings released: US$1.94 loss per share (vs US$8.36 loss in FY 2022)

New minor risk - Shareholder dilution

CRISPR Therapeutics AG has filed a Follow-on Equity Offering in the amount of $279.999863 million.

CRISPR Therapeutics Announces U.S. Food and Drug Administration (FDA) Approval of CASGEVY™ for the Treatment of Transfusion-Dependent Beta Thalassemia

CRISPR Therapeutics AG Announces Resignation of Phuong Khanh Morrow as Chief Medical Officer, Effective January 26, 2024

CRISPR Therapeutics AG and Vertex Pharmaceuticals Incorporated Announce Receipt of the First-Ever Approval of a CRISPR-Based Gene-editing Therapy in the United States

CRISPR Therapeutics Announces Updates to Immuno-Oncology Pipeline and Expansion into Autoimmune Disease

Third quarter 2023 earnings released: US$1.41 loss per share (vs US$2.24 loss in 3Q 2022)

CRISPR Therapeutics Announces Completion of FDA Advisory Committee Meeting for Exagamglogene Autotemcel (exa-cel) for Severe Sickle Cell Disease

CRISPR Therapeutics Announces Leadership Transition Effective September 15, 2023

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released: US$0.98 loss per share (vs US$2.40 loss in 2Q 2022)

Insufficient new directors

New minor risk - Shareholder dilution

Vertex Pharmaceuticals Incorporated and Crispr Therapeutics Announces Positive Results from Pivotal Trials of Exa-Cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease

Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics Announce FDA Accepts Biologics License Applications for Exagamglogene Autotemcel (Exa-Cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

First quarter 2023 earnings released: US$0.67 loss per share (vs US$2.33 loss in 1Q 2022)

CRISPR Therapeutics Appoints Alex Harding, M.D., M.B.A., as Head of Business Development, Effective January 5, 2023

CRISPR Therapeutics AG Provides Update on Its Ongoing Phase 1 Carbon(Tm) Trial of Ctx110(R)

CRISPR Therapeutics Announces Executive Changes

CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX130™ for the Treatment of Cutaneous T-Cell Lymphomas (CTCL)

Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics Announce Global exa-cel Regulatory Submissions for Sickle Cell Disease and Beta Thalassemia in 2022

Second quarter 2022 earnings released: US$2.40 loss per share (vs US$10.01 profit in 2Q 2021)

Investor sentiment improved over the past week

CRISPR Therapeutics AG Elects Maria Fardis as Board Member

CRISPR Therapeutics Presents Positive Results from its Phase 1 COBALT™-LYM Trial of CTX130™ in Relapsed or Refractory T Cell Malignancies at the 2022 European Hematology Association (EHA) Congress

Investor sentiment improved over the past week

Investor sentiment improved over the past week

CRISPR Therapeutics AG Announces the Appointment of Phuong Khanh Morrow as Chief Medical Officer, Effective May 23, 2022

CRISPR Therapeutics Announces Oral Presentation of New Clinical Data on Anti-CD70 Allogeneic CAR-T Therapy CTX130™ for Patients with T-cell Lymphoma at the Annual European Hematology Association (EHA) 2022 Hybrid Congress

First quarter 2022 earnings released: US$2.33 loss per share (vs US$1.51 loss in 1Q 2021)

CRISPR Therapeutics Proposes Appointment of Maria Fardis to the Board of Directors

Shareholder Returns

Price Volatility

About the Company

CRISPR Therapeutics AG Fundamentals Summary

12.7x

-30.7x

Earnings & Revenue